Clinical Trials Browser

Mesothelioma, Malignant, Esophageal Neoplasms, Lung Neoplasms

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT07443020 2026-04-07

RIOT 4B

Phase 1 Recruiting

10 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Pleural Effusion, Malignant

NCT07510815 2026-04-06

DUAL-MESO-NK

Phase 1/2 Recruiting

36 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT07277413 2026-04-03

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Phase 1 Recruiting

260 enrolled

GastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

NCT06097728 2026-04-02

eVOLVE-Meso

Phase 3 Recruiting

825 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT06251310 2026-04-01

SW-682 in Advanced Solid Tumors

Phase 1 Recruiting

186 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05655078 2026-03-30

HIT-Meso

Phase NA Recruiting

148 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT06840834 2026-03-16

Bi-MAPS

Phase 2 Recruiting

38 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT06051695 2026-02-20

EVEREST-2

Phase 1/2 Recruiting

474 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms

NCT06566079 2026-02-17

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

Phase 1 Recruiting

100 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Neoplasm Metastasis

NCT07126509 2026-02-17

Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

Phase NA Recruiting

30 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT07403630 2026-02-17

IT-TCP POS

Phase NA Recruiting

300 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Squamous Cell, Melanoma, Multiple Myeloma, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04981119 2026-02-13

BASECAMP-1

Recruiting

200 enrolled

BreastGastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05568680 2026-02-10

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Phase 1 Recruiting

42 enrolled

GynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Ovarian Neoplasms

Clinical Trials

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

RIOT 4B

DUAL-MESO-NK

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

eVOLVE-Meso

SW-682 in Advanced Solid Tumors

HIT-Meso

Bi-MAPS

EVEREST-2

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

IT-TCP POS

BASECAMP-1

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma